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The Reduced Expression of the HADH2 Protein Causes X-Linked
Mental Retardation, Choreoathetosis, and Abnormal Behavior
Claus Lenski, R. Frank Kooy, Edwin Reyniers, Daniela Loessner, Ronald J. A. Wanders,
Birgitta Winnepenninckx, Heide Hellebrand, Stefanie Engert, Charles E. Schwartz,
Alfons Meindl, and Juliane Ramser
Recently, we defined a new syndromic form of X-linked mental retardation in a 4-generation family with a unique clinical
phenotype characterized by mild mental retardation, choreoathetosis, and abnormal behavior (MRXS10). Linkage analysis
in this family revealed a candidate region of 13.4 Mb between markers DXS1201 and DXS991 on Xp11; therefore, mutation
analysis was performed by direct sequencing in most of the 135 annotated genes located in the region. The gene (HADH2)
encoding L-3-hydroxyacyl-CoA dehydrogenase II displayed a sequence alteration (c.574 CrA; p.R192R) in all patients
and carrier females that was absent in unaffected male family members and could not be found in 2,500 control X
chromosomes, including in those of 500 healthy males. The silent CrA substitution is located in exon 5 and was shown
by western blot to reduce the amount of HADH2 protein by 60%–70% in the patient. Quantitative in vivo and in vitro
expression studies revealed a ratio of splicing transcript amounts different from those normally seen in controls. Ap-
parently, the reduced expression of the wild-type fragment, which results in the decreased protein expression, rather
than the increased amount of aberrant splicing fragments of the HADH2 gene, is pathogenic. Our data therefore strongly
suggest that reduced expression of the HADH2 protein causes MRXS10, a phenotype different from that caused by 2-
methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, which is a neurodegenerative disorder caused by missense mu-
tations in this multifunctional protein.
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The prevalence of X-linked mental retardation (XLMR) has
been estimated to be 1 in 500 males. More than 250 dif-
ferent XLMR entities have been described to date.1–4 Of
these entities, ∼165 were classified as syndromic forms
characterized by specific biochemical, morphological, or
neurological features associated with mental retardation
(MR).4 Recently, we described a new XLMR syndrome with
a unique clinical phenotype characterized by mild MR,
choreoathetosis, and abnormal behavior (MRXS10 [MIM
%300220]) in a large Luxembourgian family classified as
having MRXS10.5 This 4-generation family included five
affected males and four unaffected carrier females (fig. 1).
Choreoathetosis, the main distinguishing feature of the
disorder, is characterized by involuntary, irregular, purpose-
less, nonrhythmic, abrupt, and rapid movements, as de-
scribed in detail by Reyniers and colleagues.5
We have refined the linkage interval for the MRXS10-
affected family to a region of 13.4 Mb on the short arm
of the X chromosome, on Xp11.4-21.5 The establishment
of a gene catalogue for the defined interval revealed a total
of 135 annotated genes, and mutation screening was per-
formed on genomic DNA and on cDNA. Through use of
standard protocols, DNA and RNA were extracted from
blood samples and immortalized lymphoblastoid cell lines
that were established from peripheral lymphocytes. At the
genomic level, the screening was performed by exon se-
quencing with the adjacent intronic sequences through
use of Big Dye kits (Perkin Elmer), with separation of the
fragments on an ABI capillary sequencer (ABI 3100). Ini-
tially, all 10 known MRX (nonsyndromic forms of MR)
and MRXS (syndromic forms of MR) genes within the
13.4-Mb linkage interval between markers DXS1201 and
DXS991 were screened for mutations by sequencing ge-
nomic DNA and cDNA (appendix A; genes are indicated
by a superscript “MRX”). All of them could be excluded
as causative of MRXS10. Next, 90 of the 125 remain-
ing annotated genes within the candidate interval were
screened for mutations (appendix A; genes are highlighted
in bold). These screening efforts revealed a silent CrA
substitution in patient IV-1 (fig. 1; indicated with an ar-
row) in exon 5 (c.574CrA; p.R192R) of the HADH2 gene
(MIM *300256; GenBank accession number NM_004493)
(fig. 2A). For patient IV-1, in addition to the expected 515-
bp fragment, RT-PCR revealed a second visible 406-bp frag-
ment not seen in controls (fig. 2B). Subsequent sequencing
of these two fragments demonstrated the loss of exon 5
in the 406-bp fragment, which introduces a premature
stop codon in exon 6 (fig. 2C and 2D). A third fragment,
obtained by cloning experiments but not visible in fig. 2B,
lacks 27 bp of the 3′ end of exon 5. The novel c.574CrA
mutation segregates with the disease in the family and
was not found in 2,500 control X chromosomes (2,000 X
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Figure 1. Pedigree of the MRXS10-affected family. Affected males
are indicated by black boxes, the obligate carrier females by circles
with dots. The index patient (IV-1) is marked with an arrow.
Table 1. Determination of MHBD Activity
Protein
Amount (%) of Activity
Patient IV-1 Patient IV-3 Control 1 Control 2
2-Methyl-acetoacetyl-CoA 2.28 (90) 2.02 (80) 2.62 (104) 2.42 (96)
Acetoacetyl-CoA 89 (130) 76 (111) 74 (108) 63 (92)
Ratio .026 (70) .027 (73) .035 (95) .039 (105)
NOTE.—The amount is indicated in nmol/min/mg (percentage of control average). The
activity in cultured Epstein Barr–virus immortalized lymphoblastoid cell lines from two
patients with MRXS10 and from two unaffected control subjects was measured spectro-
photometrically in the reverse direction by following the decrease in absorbance at 340
nm at 37C. Acetoacetyl-CoA was measured as a reference. The standard reaction medium,
with a total volume of 250 ml, contained the following components: 50 mM MES/100 mM
potassium phosphate buffer (pH 6.16), 0.1% (wt/vol) Triton X-100, 0.2 mM NADH, and
0.32 mg/ml lymphoblastoid cell homogenate protein. Reactions were started by the ad-
dition of 2-methyl-acetoacetyl-CoA at a final concentration of .05 mM. Activity is given
as a mean of two independent measurements.
chromosomes from 1,000 healthy white females and 500
X chromosomes from 500 healthy white males, both groups
of European origin), as demonstrated by denaturing high-
pressure liquid chromatography (WAVE [Transgenomics]).
This experiment was done with a 51%–65% gradient of B
buffer and a running temperature of 61C. For PCR am-
plification, the HADH2-WAVE primer pair 5′-AAG TTC
TCC AGG GAT AGT GG-3′ (forward) and 5′-CCC AAT CCC
AGG TAT GAT GG-3′ (reverse) was used. Heteroduplex
conformation was made possible by adding female wild-
type DNA to DNA from hemizygous males.
To quantify the levels of full-length and aberrant tran-
scripts in MRXS10-affected patients IV-1 and IV-3 and in
healthy white controls of European origin, real-time ex-
periments were performed using transcript-specific Taq-
Man primers and probes on RNA extracted from lympho-
blastoid cell lines (fig. 3).
PCR amplification and detection were performed on a
Sequence Detection System (ABI PRISM 7000 [Applied Bio-
systems]), with application of the standard two-step proto-
col (45 cycles; annealing temperature 61C) recommended
by the company. TaqMan primer transcripts were designed
by TibMolbiol for the different HADH2 transcripts. For the
full-length transcript, primers 5′-GCC TTC GAG GGT CAG
GTT G-3′ (forward) and 5′-GGG AGG CTG GTC AGC AGT-
3′ (reverse) and probe 5′-FAM-CCA AAC AGA CCT GGG
GCA ATG GTC A-TMR-3′ were used. For the Dexon 5 tran-
script, primers 5′-CCT TCG AGG GTC AGG TCT GTT-3′
(forward) and 5′-GTG AGC ATA CTC AGC AGG GTC AC-
3′ (reverse) and probe 5′-FAM-TGA CCA GCC TCC CAG
AGA AAG TGT GC-TMR-3′ were used. For the D27-bp tran-
script, primers 5′-GGT CAT CAT CAA CAC TGC CAG TGT
G-3′ (forward) and 5′-CCA AAC AGA CCT ATG GGA GCC
AGA T-3′ (reverse) and probe 5′- FAM-CCC CTT GGA AGC
AGA GTA TGC AGC TTG TC-TMR-3′ were used.
These experiments revealed that, on one hand, the level
of full-length transcript was reduced to one-third in both
affected males, whereas, on the other hand, the levels of
the two aberrant transcript variants (Dexon 5 and D27 bp)
were increased 3.5-fold and 14-fold, respectively, as com-
pared with the controls. In relation to the full-length tran-
script expressed in controls, the Dexon 5 transcript ac-
counts for only ∼5.5%, and the variant lacking 27 bp
accounts for only ∼0.4%, which makes a biological rele-
vance for the latter variants unlikely (fig. 3). To demon-
strate that the detected CrA mutation is causative of the
misregulated splicing process, in vitro splicing and expres-
sion experiments were performed. We cloned the genomic
HADH2 sequence of exons/introns 4–6 with and without
the c.574CrA substitution in a p-Target mammalian ex-
pression vector (Promega), followed by an in vitro splicing
process by use of the HeLa Scribe nuclear extract in vitro
transcription system (Promega) and subsequent mRNA
isolation. By sequencing the cloned HADH2 fragments, we
made sure that there was no difference between the wild-
type and the mutated fragment other than the c.574CrA
substitution. Real-time PCR analysis with the mRNA ob-
tained from these in vitro experiments confirmed that the
altered amounts of the transcripts in the MRXS10-affected
patients were due to the c.574CrA substitution. Here, the
full-length transcript was reduced ∼50%, and the amount
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Figure 2. A, Silent c.574CrA substitution in exon 5 of HADH2. Left, Sequence of MRXS10-affected patient IV-1, who harbors the
c.574CrA substitution. Right, Wild-type sequence of a healthy control. B, RT-PCR amplification of the HADH2 gene through use of
primers HADH2-cF2 and HADH2-cR2. In patient IV-1 (lane 2), the amplification results in a 515-bp wild-type fragment and in a second,
shorter fragment of 406 bp. In the healthy control (lane 3), only the wild-type 515-bp fragment is visible. The negative template
control is shown in lane 4. Molecular weight marker LSV is shown in lane 1. C, cDNA sequences of the exon boundaries (between exons
4 and 5) of the 515-bp fragment with exon 5 (top) and of the exon boundaries (exons 4–6) of the 416-bp fragment lacking exon 5
(bottom). D, Genomic structure of HADH2. The gene consists of six coding exons, which result in a 261-aa protein with a conserved
short-chain dehydrogenase domain at amino acid positions 28–257 (hatched boxes). The c.574CrA substitution is located in exon 5.
In the transcript variant lacking exon 5, a premature stop codon is created in exon 6. The position of the primers used for cDNA
amplification, as shown in panel B, are indicated by “cF2” and “cR2.’
of the Dexon 5 variant was increased twofold. The D27-
bp transcript was increased fourfold.
One possible explanation for the observed incomplete
and skewed splicing is that the detected CrA substitution
is located in a regulatory element, which is important for
the correct splicing process. Such additional regulatory el-
ements, apart from the classic GU/AG sites, are, for exam-
ple, exonic-splice-enhancer (ESE) or exonic-splice-silencer
sites or specific stem-loop structures that can impede or
promote efficient exon recognition.6 These regulatory el-
ements normally stabilize the correct quantitative ratio of
the different transcript variants of a gene. An alteration
of such an element leads to a shift of this ratio and there-
fore to an over- or underexpression of the single variants.
For instance, in the tau gene, which is associated with
frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17 [MIM #600274]), a destabilized
splicing regulatory element is causative of the altered
amount of the exon 10–containing variant that is respon-
sible for the aberrant neuronal development.7
As in the case of a recently described mutation in a
putative ESE in the renin receptor gene, which causes MR
in association with epilepsy (XMRE [MIM #300423]),8 the
mutation in the HADH2 gene results in an altered splicing
process. However, in contrast to the XMRE-affected family
for which we discussed the generation of aberrant dimeric
www.ajhg.org The American Journal of Human Genetics Volume 80 February 2007 375
Figure 3. Transcript quantification applying real-time PCR.
Whereas the full-length transcript is reduced to one-third in pa-
tients IV-1 and IV-3, as compared with the mean value of seven
healthy controls (a), the Dexon 5 variant is increased 3.5-fold in
the patient (b), and the transcript variant that lacks 27 bp of the
3′ end of exon 5 is increased 14-fold in the patients (c). RNA
samples from the two patients and the seven controls were reverse
transcribed (cDNA Synthesis Kit [Amersham]).
Figure 4. Detection of the HADH2 protein by western-blot anal-
ysis. Amounts between 50 and 100 mg of total protein were loaded.
As reference, protein b-actin was detected. The ∼27-kDa bands
representing the HADH2 protein of patient IV-1 with MRXS10 show
a weaker signal than do the bands of control individuals 1 and 2.
proteins as causative of the syndrome, we hypothesized
that the reduced expression of the HADH2 protein was
the cause of MRXS10. To support this hypothesis, we per-
formed western-blot analysis. Proteins were isolated from
lymphoblastoid cell lines of an affected male (IV-1) and
two control individuals, measured by the method of Brad-
ford,9 were separated on a 12% polyacrylamid gel (SDS-
PAGE), and were transferred to a PROTRAN nitrocellulose
membrane (Schleicher & Schuell). After blocking the mem-
brane overnight with 5% BSA, the HADH2 protein was
detected by a polyclonal antibody (IMG3785 [IMGENEX)].
For normalization, b-actin was used and quantities were
calculated by densidometric analysis with the SCION IM-
AGE system. As shown in figure 4, the amount of the
HADH2 protein in the affected male is reduced compared
with that of controls. In two independent experiments,
densidometric calculation revealed an average decrease of
∼60% in patient IV-1.
Ofman and colleagues10 reported missense mutations in
the HADH2 gene that result in 2-methyl-3-hydroxybutyryl-
CoA dehydrogenase (MHBD) deficiency (MIM #300438),
an inborn error of isoleucine degradation. It is associated
with severe neurological abnormalities, such as the grad-
ual loss of mental and motor skills that progresses to
profound developmental regression, choreoathetosis, near
blindness, and epilepsy. MHBD catalyzes the transition of
2-methyl-3-hydroxybutyryl-CoA to 2-methyl-acetoacetyl-
CoA, which, in turn, is split into acetyl CoA and propionyl
CoA. Whereas patients with loss-of-function mutations
in the gene encoding MHBD have only very low residual
amounts of MHBD activity, our patients show almost nor-
mal MHBD activities, amounting to 85% of the level in
controls, which indicates no major decrease in MHBD ac-
tivity (table 1). This result, together with the fact that the
phenotype of MHBD deficiency is much more severe than
the MRXS10 phenotype, supports our assumption that the
clinical phenotype of MRXS10 is distinct from MHBD de-
ficiency and is caused by a different molecular mechanism.
To determine whether HADH2 is mutated in other XLMR
entities, we screened another 18 syndromic or nonsyn-
dromic entities that are linked to the same genomic in-
terval. However, we failed to detect additional alterations.
We also investigated six patients with sporadic MR who
present with choreoathetoid movements, and we did not
identify additional mutations in HADH2. These results
support the expected uniqueness of the phenotype—that
is, the MRXS10 syndrome and the genetic aberration.
Here, we report the finding of a novel and unique mu-
tation in the HADH2 gene. We demonstrated that the
change is causative of an aberrant transcript-splicing pro-
cess in the gene, which results in a lower level of wild-
type HADH2 and the increase of minor aberrant fragments
in the patients as compared with controls. Reduced ex-
pression of the HADH2 protein could be demonstrated for
the patient with MRXS10 by western-blot analysis. This
seems not to impair its role in isoleucine degradation;
rather, it impairs one or more other functions attributed
to this multifunctional protein. The mutated HADH2 gene
is widely expressed and encodes a homotetrameric pro-
tein, with a molecular weight of 108 kDa, with multi-
functional capacities. Since several researchers have re-
ported different functions of this protein, different acro-
nyms have been used to describe it, such as ERAB (en-
doplasmic reticulum–associated amyloid-b–binding pro-
tein), ABAD (amyloid b peptide–binding alcohol dehydro-
genase type II), HSD10 (17 b-hydroxysteroid dehydroge-
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nase type 10), MHBD, and SCHAD (3-a hydroxyacyl-CoA
dehydrogenase, short chain).
Tieu et al.11 showed, in a mouse-model system, that in-
creased expression of HADH2 protects against specific hall-
marks of Parkinson disease (PD [MIM #168600]); in ac-
cordance with this, the HADH2 expression was shown to
be reduced in midbrains of patients with PD. However,
reexamination of the clinical phenotype of the patients
with MRXS10, especially the two who had reached ages
66 and 74 years, did not reveal any clinical features cor-
responding to those of PD.
Another described function of HADH2 is its interaction
with beta-amyloid (Abeta), a protein that builds up in
the brain of patients with Alzheimer disease (AD [MIM
#104300]) and collects in clumps or plaques. Lustbader et
al.12 demonstrated that HADH2 and the Abeta protein in-
teract directly in the mitochondria of patients with AD
and increases the mitochondrial toxicity of Abeta. Further-
more, He and coworkers13 described HADH2 as a mito-
chondrial protein that is able to oxidize and therefore to
inactivate the sex steroid hormones 17b-estradiol and di-
hydroandrosterone. He et al.13 proposed that it could
weaken the protective effects of estrogen against AD and
generate aldehyds in neurons in the brain, which would
mean that high concentrations of HADH2 could be a risk
factor for AD. So far, such conclusions are in agreement
with our observations, since patients with MRXS10 have
not yet developed symptoms of AD. However, additional
functional studies are required to clear up our understand-
ing of the disturbed neuronal regulations caused by the
reduced protein expression of HADH2 in MRXS10.
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Appendix A
Annotated Genes Located in the Candidate Interval
Annotated genes in the candidate interval are
PPP1R2P9, MAOAMRX, MAOB, NDPMRX, EFHC2,
FUNDC1, DUSP21, UTX, Cxorf36, ZNF673,
ZNF674MRX, CHST7, SLC9A7, RP2, PHF16, RGN,
NDUFB11, RBM10, UBE1, INE1, PP3895, PCTK1,
USP11, ZNF157, ZNF41MRX, ARAF, SYN1, TIMP1,
CFP, ELK1, UXT, ZNF81MRX, ZNF182, ZNF630, SSX-
Cluster (7 genes: SSX1, -3, -4, -4B, -5, -6, and -9),
PNPK6288*, SLC38A5, FTSJ1MRX, PORCN, EBP,
OATL1, RBM3, WDR13, WAS, SUV39H1, GATA1,
HDAC6, ERAS, PCSK1N, TIMM17B, PQBP1MRX,
SLC35A2, PIM2, OTUD5, KCND1, GRIPAP1, TFE3,
CCDC120, PRAF2, WDR45, GPKOW, FLJ21687*,
PLP2, LMO6, SYP, CACNA1F, CCDC22, FOXP3,
PPP1R3F, GAGE-Cluster (8 genes: GAGE2, -8, -4, -6, -5,
-7B, -7, and -1), PAGE1, PAGE4, LOC158572*, CLCN5,
AKAP4, CCNB3, DGKK, SHROOM4MRX, BMP15,
NUDT10, LOC340602*, NUDT11, GSPT2, MAGED1,
MAGED4, LOC401589*, XAGE2, XAGE1, SSX8, SSX7,
SSX2, SPANXN5, XAGE5, XAGE3, TMEM29, GPR173,
TSPYL2, JARID1CMRX, IQSEC2, SMC1A, RIBC1,
HADH2, HUWE1, PHF8MRX, FAM120C, WNK3, TSR2,
FGD1, GNL3L, ITIH5L, MAGED2, TRO, PFKFB1,
APEX2, ALAS2, PAGE2B, PAGE2, FAM104B, PAGE5,
PAGE3, MAGEH1, and USP51. Screened genes are indi-
cated in bold. Genes excluded from screening comprise
SSX-, MAGE-, XAGE-, and PAGE- genes, as well as five
genes associated with other diseases. Genes associated
with other diseases are indicated in italics. Genes already
associated with MR are indicated by a superscript “MRX.”
Genes annotated by National Center for Biotechnology
Information but still awaiting an approved symbol given
by the HUGO Nomenclature Committee are marked with
an asterisk (*).
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for HADH2
[accession number NM_004493])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MRXS10, HADH2, FTDP-17, XMRE,
MHBD deficiency, PD, and AD)
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